Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | PKLR | P30613 | 1/20 | 0.35 |
| ▸ | F11 | P03951 | 3/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 4/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23089175 | 0.84 | CA12 (0.39) | CA12CA1CA2CA9CA7 | |
| SCHEMBL3566914 | 0.84 | CA12 (0.39) | CA12CA1CA2CA9CA7 | |
| SCHEMBL759250 | 0.84 | CA12 (0.39) | CA12CA1CA2CA9CA7 | |
| SCHEMBL3561664 | 0.82 | GPR119 (0.41) | — | |
| SCHEMBL18274666 | 0.80 | F11 (0.35) | F11OPRL1 | |
| SCHEMBL23647368 | 0.79 | CA12 (0.43) | CA12CA1CA2CA9CA7 | |
| SCHEMBL761722 | 0.78 | PRKCA (0.51) | CA12CA1CA2CA9CA7 | |
| SCHEMBL2560399 | 0.78 | MBOAT4 (0.38) | — | |
| SCHEMBL3557514 | 0.76 | OPRL1 (0.42) | PKLRSPROPRL1OPRD1 | |
| SCHEMBL5381132 | 0.75 | CA12 (0.46) | CA12CA1CA2CA9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825135-B2 | Heteroaryl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| US-20070254880-A1 | Heteroaryl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254880-A1 | Heteroaryl Piperidine Glycine Transporter Inhibitors | SLC1A2, SLC1A1, SLC1A3 | CA12 4864/4885CA1 4422/4885CA2 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.